Abstract:The nuclear enzyme topoisomerase I (topo I) has been recently recognized as the target for the anticancer drug camptothecin (CPT) and its derivatives. Two of the agents that target this enzyme--topotecan (TPT) and CPT-11--appear to be active against a broad range of human tumors. In the following presentation, we review 1) the role of topo I in normal cells, 2) the chemistry and proposed mechanism of action of CPT and its analogues, 3) the results of preclinical and clinical testing of TPT and CPT-11, and 4) mechanisms of resistance to these agents. In normal cells, topo I is thought to be involved in gene transcription and DNA replication. During the course of its normal catalytic cycle, topo I transiently forms a covalent bond with DNA. CPT and its derivatives slow the religation step of the enzyme and stabilize the covalent adduct between topo I and DNA. In S-phase cells, advancing replication forks convert these topo I-DNA adducts into double-strand breaks that appear to be responsible for the cytotoxicity of these agents. Preclinical studies demonstrate antineoplastic activity for TPT and CPT-11 in a variety of tumor models. Phase I studies have identified neutropenia as the dose-limiting toxicity for both drugs. Gastrointestinal effects might also be dose-limiting for CPT-11 administered on some schedules. CPT-11 has shown antitumor activity in phase II trials for patients with carcinomas of lung, cervix, ovary, colon, and rectum and for patients with non-Hodgkin's lymphoma. Phase II studies of TPT are in progress. Resistance to the cytotoxic effects of these agents might result from decreased production of topo I or from production of a mutated form of topo I. In addition, decreased metabolic activation of CPT-11 (which is a pro-drug) and active efflux of TPT by P-glycoprotein-mediated transport might contribute to resistance. As agents with a novel mechanism of action, tolerable toxicity, and encouraging antitumor activity in early clinical trials, TPT and CPT-11 are undergoing further clinical development. If these agents can be successfully combined with other active chemotherapy agents, the topo I-directed agents offer the potential for significant advances in the treatment of patients with a variety of malignancies.

Two Novel Camptothecin Derivatives Inhibit Colorectal Cancer Proliferation Via Induction of Cell Cycle Arrest and Apoptosis in Vitro and in Vivo

Identification of 7-Aminourea or Aminothiourea Derivatives of Camptothecin As Selective Topoisomerase I Inihibitors with Anti-Colorectal Cancer Activities

Identification of 7-aminourea or 7-aminothiourea derivatives of camptothecin as selective topoisomerase I inhibitors with anti-colorectal cancer activities

Design, Synthesis, and Cytotoxic Activity of Novel 7-Substituted Camptothecin Derivatives Incorporating Piperazinyl-Sulfonylamidine Moieties.

Anti-proliferative and pro-apoptotic effect of CPT13, a novel camptothecin analog, on human colon cancer HCT8 cell line

The current status of camptothecin analogues as antitumor agents.

Novel 9-Benzylaminoacridine Derivatives as Dual Inhibitors of Phosphodiesterase 5 and Topoisomerase II for the Treatment of Colon Cancer

Design, Semisynthesis and Potent Cytotoxic Activity of Novel 10-Fluorocamptothecin Derivatives

Design and One-Pot Synthesis of New 7-Acyl Camptothecin Derivatives As Potent Cytotoxic Agents

Antitumor activity and pharmacokinetics following oral administration of natural product DNA topoisomerase I inhibitors 10-hydroxycamptothecin and camptothecin in SCID mice bearing human breast cancer xenografts.

Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?

Perspectives on Biologically Active Camptothecin Derivatives

Design and Synthesis of Novel PEG-conjugated 20(S)-Camptothecin Sulfonylamidine Derivatives with Potent in Vitro Antitumor Activity Via Cu-catalyzed Three-Component Reaction

Improved Anti-Tumor Activity of Fluorinated Camptothecin Derivatives 9-Fluorocamptothecin and 7-Ethyl-9-fluorocamptothecin on Hepatocellular Carcinoma by Targeting Topoisomerase I.

Structure-Based Drug Design and Identification of H2O-Soluble and Low Toxic Hexacyclic Camptothecin Derivatives with Improved Efficacy in Cancer and Lethal Inflammation Models in Vivo

Current status of CPT and its analogues in the treatment of malignancies

Design, Synthesis, Mechanisms of Action, and Toxicity of Novel 20(S)-Sulfonylamidine Derivatives of Camptothecin As Potent Antitumor Agents

Design and Synthesis of Novel 7-[(N-substituted-thioureidopiperazinyl)-methyl]-camptothecin Derivatives As Potential Cytotoxic Agents.

Drug combinations of camptothecin derivatives promote the antitumor properties

Synthesis and Antitumor Activity of Novel 10-Substituted Camptothecin Analogues.

Topoisomerase I-mediated antiproliferative activity of 10-substituted and 12-substituted homocamptothecins